All reports

All KCE reports are available in Dutch, French and English under several formats. Form and language of the reports

Publication year:
General domain:
Specific domain:
  1. Antibiotic_Policy

    Proposals for a more effective antibiotic policy in Belgium

    KCE Reports 311 (2019)  

    https://kce.fgov.be/en/proposals-for-a-more-effective-antibiotic-policy-in-belgium
  2. Children in a playground

    Cost-effectiveness analysis of HPV vaccination of boys in Belgium

    KCE Reports 308 (2019) The vaccine for the human papilloma virus (HPV) which causes cervical cancer was introduced about ten years ago in Belgium, but only girls benefit from it. However, it is now established that this same virus is also involved in other cancers, including throat cancer. The recommendations have thus been reviewed and here, as in most western countries, it is now recommended to vaccinate boys too.

    https://kce.fgov.be/en/cost-effectiveness-analysis-of-hpv-vaccination-of-boys-in-belgium
  3. Senior couple on contry bike

    Statins for the primary prevention of cardiovascular events

    KCE Reports 306 (2019) A healthy lifestyle remains the most effective way of avoiding cardiovascular diseases and their consequences. Yet since 2002, the annual number of people who use cholesterol-lowering drugs from the statin family increased from 400,000 to 1,500,000. Currently, 25% of the population aged 40 and above take these drugs. Despite decreases in price due to the fact that all statins now exist in generic form, their total cost still stands at 160 million euros annually.

    https://kce.fgov.be/en/statins-for-the-primary-prevention-of-cardiovascular-events

  4. Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C

    KCE Reports 276 (2016)

    https://kce.fgov.be/en/economic-evaluation-of-novel-direct-acting-antiviral-daa-treatment-strategies-for-chronic-hepatitis

  5. Use of pneumococcal vaccines in the elderly: an economic evaluation

    KCE Reports 274 (2016) Supplementary material pdf fileR274_Supplementary-file_Univariate-sensitivity-analyses (13.95 MB) pdf fileR274_Supplementary-file_Sensitivity-analyses_PPV23-price (1.1 MB) pdf fileR274_Supplementary-file_Multivariate-sensitivity-analyses_Net-benefit-Box-plots (1.16 MB) pdf fileR274_Supplementary-file_Multivariate-sensitivity-analyses_CEAFs-and-CE-planes (58.74 MB) The results are also available in a searchable spreadsheet-database format for all scenario and sensitivity analyses.

    https://kce.fgov.be/en/use-of-pneumococcal-vaccines-in-the-elderly-an-economic-evaluation

  6. Future scenarios about drug development and drug pricing

    KCE Reports 271 (2016)

    https://kce.fgov.be/en/future-scenarios-about-drug-development-and-drug-pricing

  7. Towards a better managed off-label use of drugs

    KCE Reports 252 (2015)

    https://kce.fgov.be/en/towards-a-better-managed-off-label-use-of-drugs

  8. Publicly funded Practice-oriented Clinical Trials

    KCE Reports 246 (2015)

    https://kce.fgov.be/en/publicly-funded-practice-oriented-clinical-trials

  9. A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study

    KCE Reports 231 (2014)

    https://kce.fgov.be/en/a-quadrivalent-vaccine-against-serogroup-b-meningococcal-disease-a-cost-effectiveness-study

  10. The long-term efficacy of psychotherapy, alone or in combination with antidepressants, in the treatment of adult major depression

    KCE Reports 230 (2014)

    https://kce.fgov.be/en/the-long-term-efficacy-of-psychotherapy-alone-or-in-combination-with-antidepressants-in-the

  11. Supportive treatment for cancer – Part 3: Treatment of pain: most common practices

    KCE Reports 211 (2013)

    https://kce.fgov.be/en/supportive-treatment-for-cancer-%E2%80%93-part-3-treatment-of-pain-most-common-practices

  12. Barriers and opportunities for the uptake of biosimilar medicines in Belgium

    KCE Reports 199 (2013)

    https://kce.fgov.be/en/barriers-and-opportunities-for-the-uptake-of-biosimilar-medicines-in-belgium

  13. Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy

    KCE Reports 191 (2012)

    https://kce.fgov.be/en/supportive-treatment-for-cancer-part-2-prevention-and-treatment-of-adverse-events-related-to

  14. [Vaccine safety surveillance in Belgium : place and limits of a background rate approach]

    KCE Reports 188 (2012)

    https://kce.fgov.be/en/vaccine-safety-surveillance-in-belgium-place-and-limits-of-a-background-rate-approach

  15. [Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium]

    KCE Reports 157 (2011)

    https://kce.fgov.be/en/economic-evaluation-of-antiviral-treatment-of-chronic-hepatitis-b-in-belgium

  16. Pharmacological prevention of fragility fractures in Belgium

    KCE Reports 159 (2011)

    https://kce.fgov.be/en/pharmacological-prevention-of-fragility-fractures-in-belgium

  17. Drug reimbursement systems: international comparison and policy recommendations

    KCE Reports 147 (2010)

    https://kce.fgov.be/en/drug-reimbursement-systems-international-comparison-and-policy-recommendations

  18. [Statins in Belgium: utilization trends and impact of reimbursement policies]

    KCE Reports 141 (2010)

    https://kce.fgov.be/en/statins-in-belgium-utilization-trends-and-impact-of-reimbursement-policies

  19. Seamless care with regard to medications between hospital and home

    KCE Reports 131 (2010)

    https://kce.fgov.be/en/seamless-care-with-regard-to-medications-between-hospital-and-home

  20. Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium. Part 1: Literature review and results of a national study

    KCE Reports 127 (2010)

    https://kce.fgov.be/en/cost-effectiveness-of-antiviral-treatment-of-chronic-hepatitis-b-in-belgium-part-1-literature-review

Pages